A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2011
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 17 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2010 New trial record